- Kedrion has in-licensed ProMetic´s crop convalescent technology
- $30 M abeyant anniversary acquirement acquired from ProMetic sales of the aboriginal hyperimmune artefact in the U.S. bazaar
- Incorporation of ProMetic´s technology in Kedrion´s accomplishment action
MONTREAL, QUEBEC--(Marketwire - February 27, 2008) - ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI) appear today that it has active the absolute acceding for development of two hyperimmunes with Kedrion S.p.A. ("Kedrion").
Terms of this acceding alarm for upfront and anniversary payments, as able-bodied as account fees to ProMetic. Potential revenues to ProMetic from Hepatitis B Hyperimmune absolute sales in North America are to beat $30 M annually, which are accepted to arise in 2011.
The aboriginal artefact to be developed will ambition the Hepatitis B Hyperimmune bazaar which is currently estimated in Europe and in the U.S. to be at $200 M and is accepted to be at $400 M by 2015.
Kedrion has in-licensed ProMetic´s technologies for the accomplishment of hyperimmune articles in Europe. Royalties, licensing and account fees for the sales of articles in Europe will be paid by Kedrion to ProMetic with ProMetic application the bartering rights for the absolutely developed hyperimmune articles for the North American market. ProMetic will in about-face pay Kedrion royalties on its sales of the hyperimmune articles in North America.
The artefact development program, including the analytic balloon advised to accommodated U.S. and European authoritative requirements will be adjourned by Kedrion, who will be the holder of the articles allotment for both markets.
"This acceding with Kedrion will advantage ProMetic´s adeptness to access into the North American hyperimmune artefact bazaar and aggrandize on our absolute acquirement base," commented Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.
More about Hepatitis B
HB, hepatitis B IVIG is primarily acclimated in preventing reinfection with hepatitis B in HBV absolute alarmist displace patients. It is aswell acclimated in the analysis of adroit acknowledgment to hepatitis B afterward adroit acknowledgment to claret absolute HBsAg, perinatal acknowledgment of breed complete to HBsAg-positive mothers, animal acknowledgment to HBsAg absolute persons, and domiciliary acknowledgment of breed to bodies with adroit hepatitis B virus infection. The groups usually advised at accident are hepatitis B advisers and workers, and abounding bloom affliction professionals.
More about Kedrion S.p.A.
Kedrion (www.kedrion.com) is a biopharmaceutical aggregation specialized in the development, production, commercialization and administration of plasma-derived products. Born in 2001 afterward the rationalisation and advance of added companies alive in this field, it acquired a ancestry of ability that secures it a arresting role in Italy, in Europe and in the world. Kedrion is present in over 40 countries. It´s arch appointment is in Tuscany, Castelvecchio Pascoli, abreast Lucca.
In Italy, Kedrion is a accomplice of the National Health Service for the assembly of plasma-derived alleviative products. In addition, its ability serves added cardinal partnerships with bloom institutions in added countries.
Kedrion´s activities are agitated on through altered companies and three accustomed assembly plants: Bolognana, abreast Lucca (Tuscany); S. Antimo, abreast Naples; Godollo, abreast Budapest. Kedrion works in four business areas: assembly and commercialization of plasma-derived articles acquired from the claret fractionation process; commercialization of flu vaccines and constructed biologic products; claret accumulating and commercialization in adopted markets; added activities, a allotment of them in accurate alteration of abstruse know-how. The three arch types of plasma-derived articles produced by Kedrion are: accepted and hyperimmune immunoglobulin, albumin and agglomeration factors (procoagulants and anticoagulants).
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical aggregation specialized in the research, development, accomplish and business of a array of bartering applications acquired from its proprietary Mimetic Ligand(TM) technology. This technology is acclimated in all-embracing ablution of biologics and the abolishment of pathogens. ProMetic is aswell breath in ameliorative biologic development with the mission to accompany to bazaar effective, innovative, lower cost, beneath baneful articles for the analysis of hematology and cancer. Its biologic analysis belvedere is focused on replacing complex, big-ticket proteins with constructed "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D accessories in the UK, the USA and Canada, accomplishment accessories in the UK and business development activities in the USA, Europe, Asia and in the Middle-East.
Forward Looking Statements
This columnist absolution contains advanced statements about ProMetic´s objectives, strategies and businesses that absorb risks and uncertainties. These statements are "forward-looking" because they are based on our accepted expectations about the markets we accomplish in and on assorted estimates and assumptions. Actual contest or after-effects may alter materially from those advancing in these advanced statements if accepted or alien risks affect our business, or if our estimates or assumptions about-face out to be inaccurate. Such risks and assumptions include, but are not bound to, ProMetic´s adeptness to develop, manufacture, and auspiciously commercialize value-added biologic products, the availability of funds and assets to accompany R&D projects, the acknowledged and appropriate achievement of analytic studies, the adeptness of ProMetic to crop advantage of business opportunities in the biologic industry, uncertainties accompanying to the authoritative action and accepted changes in bread-and-butter conditions. You will acquisition a added abundant appraisal of the risks that could could cause absolute contest or after-effects to materially alter from our accepted expectations on page 21 of ProMetic´s Annual Information Form for the year concluded December 31, 2006, beneath the branch "Risk Factors". As a result, we cannot agreement that any advanced account will materialize. We accept no obligation to amend any advanced account even if new advice becomes available, as a aftereffect of approaching contest or for any added reason, unless appropriate by applicative balance laws and regulations.
Contacts:
Kedrion Inquiries
Stefano Guazzini
Kedrion Scientific Director
Mob. + 39.348.6559660
s.guazzini@kedrion.com
Kedrion Communication Area
Iria Cogliani
Mob. +39.320.9191125
i.cogliani@kedrion.com
Company Inquiries: ProMetic Life Sciences Inc.
Pierre Laurin
President and CEO
+1.514.341.2115
p.laurin@prometic.com
ProMetic Life Sciences Inc.
Anne Leduc
Manager, Investor Relations & Communications
+1.514.341.2115
a.leduc@prometic.com
Investor Relations
Lippert / Heilshorn & Associates
Bruce Voss
+1.310.691.7100
BVoss@lhai.com
Media Relations
Lippert / Heilshorn & Associates
Jules Abraham
+1.212.838.3777
Jabraham@lhai.com
Echoes Financial Network Inc.
Dominic Sicotte
+1.514.842.9551
dsicotte@echoesfinancial.com
Lippert / Heilshorn & Associates
Kim Golodetz
+1.212.838.3777
KGolodetz@lhai.com
The advertisement was broadcast by Hugin.
The issuer is alone amenable for the agreeable of this announcement.
2009年12月16日星期三
ProMetic - ProMetic Announces Strategic Alliance Agreement With Wuhan Institute of Biological Products
Implementation of Plasma Fractionation Technology in China
-- WIBP to apparatus ProMetic's crop convalescent technologies for new bearing of plasma-derived articles
-- Agreement targets bartering calibration at > 1.2 actor Litres of claret annually
-- China accepted to become world's 4th better calm biologic bazaar by 2012
WUHAN, CHINA, and MONTREAL, QUEBEC--(Marketwire - March 12, 2008) - Wuhan Institute of Biological Products, ("WIBP") a accessory of China National Biotec Group ("CNBG") and ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") appear today that they accept active a cardinal accord and authorization agreement. Under the agreement of this agreement, WIBP assets absolute acceptance to ProMetic's Plasma Protein Purification System ('PPPS") for the Chinese market. Upon auspiciously implementing this technology, WIBP will be able to decidedly advance its adequacy in the accomplishment of plasma-derived articles in China.
ProMetic will abetment WIBP to apparatus a artefact development affairs that is accepting accomplished immediately, which includes training, technology transfer, and calibration up, as able-bodied as address of the analytic accomplishment facility. WIBP will crop the advance in administering the analytic trials to access appropriate authoritative approval by the Chinese State Food and Drug Administration ("SFDA"). Full calibration bartering accomplishment will crop abode at WIBP initially, could be readily implemented by added affiliated companies aural CNBG later, with the ambition to accomplish a minimum accommodation greater than 1.2 actor L claret per year.
"The affiliation of ProMetic's technologies into WIBP's absolute accomplishment basement will decidedly access WIBP's accomplishment accommodation and accredit WIBP to bigger accommodated the anytime growing appeal in China," declared Ms. Lifang Wang, President & Chief Executive Officer of CNBG.
"This acceding leverages anniversary company's ability and is accepted to body amount while bringing a new bearing of plasma-derived articles to the Chinese market," explained Mr. Gungrong Zhou, Director of WIBP. "The aggregation will advance ProMetic's new accomplishment technology to advance the above of the accepted articles as able-bodied as to acquaint new articles to accommodated the medical need."
"WIBP's accurate clue almanac in the development and business of plasma-derived articles in China is cardinal for ProMetic," commented Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic. "With its accelerated bread-and-butter growth, China is assertive to become the world's fourth better calm bazaar for pharmaceuticals."
The articles accepting targeted initially will cover thrombin, fibrinogen, albumin, intravenous immunoglobulin, Alph-1 protease inhibitor and assorted hyperimmunoglobulins such as anti-hepatitis B immunoglobulin, anti-rabies immunoglobulin, anti-tetanus immunoglobulin. These articles are accepted to alpha extensive bartering date by 2012 / 2013. Additional articles will be added later.
"We are actual admiring to acquaint this accomplishment belvedere to WIBP, which in accession to accommodate cogent crop advance over the accepted technology, aswell allows for added articles to be recovered from plasma," commented Dr. Tom Chen, Vice-President, Process Development of ProMetic BioTherapeutics, Inc.
"With advantages of college crop and added articles produced from anniversary assemblage of claret collected, this technology provides us with an ideal band-aid to best advance the adored raw material- plasma, currently in abbreviate supply, as able-bodied as augment our artefact portfolio to bigger serve medical needs in China. We are actual agitative to plan with ProMetic in implementing this able accomplishment technology," commented Dr. Xiaoming Yang, Deputy Director who is in allegation of R&D and Sales & Marketing in WIBP.
More about Wuhan Institute of Biological Products
Wuhan Institute of Biological Products ("WIBP") (www.wibp.com.cn), amid in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years acquaintance in the fields of biomedical analysis and artefact development; historically able in R&D, WIBP is the alone convention certified by accompaniment to action doctoral affairs a allotment of six Institute of Biological Products in CNBG. Today, WIBP has added than 1,000 employees, and above articles cover two dozen vaccines and claret derivatives currently marketed throughout the China.
More about China National Biotec Group
China National Biotec Group (CNBG) (www.cnbgint.com or www.cnbg.com.cn), headquartered in Beijing, China , is a state-owned action and the better biotech aggregation in China committed to discover, develop, accomplish and bazaar a ample ambit of animal bloom products, including vaccines, claret derivatives, biopharmaceuticals, analytic reagents and others. With added than 9,000 advisers and revenues of 421 actor USD in 2006, CNBG is the better ambassador of vaccines and claret derivatives in China, adequate added than 80% and 30% bazaar allotment respectively. The aggregation consists of 6 Institute of Biological Products and an all-embracing trading company.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical aggregation specialized in the research, development, accomplish and business of a array of bartering applications acquired from its proprietary Mimetic Ligand(TM) technology. This technology is acclimated in all-embracing ablution of biologics and the abolishment of pathogens. ProMetic is aswell breath in ameliorative biologic development with the mission to accompany to bazaar effective, innovative, lower cost, beneath baneful articles for the analysis of hematology and cancer. Its biologic analysis belvedere is focused on replacing complex, big-ticket proteins with constructed "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D accessories in the U.K., the U.S. and Canada, accomplishment accessories in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.
About ProMetic BioTherapeutics, Inc.
ProMetic BioTherapeutics, Inc. ("PBT") is the apple baton in claret protein fractionation technology. Headquartered in Rockville, MD (U.S.), PBT is freeholder of a unique, proven, advanced band-aid for claret fractionation Plasma Protein Purification System ("PPPS"). The advantages of PBT's protein abstraction technology are accepting added accustomed worldwide.
About ProMetic BioSciences Ltd
Using its different and proprietary Mimetic Ligand(TM) technology, ProMetic BioSciences Ltd ("PBL") specializes in the development and accomplish of able-bodied affection break abstracts which accommodate actual top levels of purification. This is accomplished by use of baby actinic affection ligands advised to bind a ambition biomolecule accurately and reversibly. In appearance of their use for the assembly of therapeutics, ProMetic's affection articles are bogus according to a austere above arrangement based on acceptable accomplishment convenance at PBL's ISO 9001:2000 certified accomplishment ability on the Isle of Man, which completed a pounds admirable 1.5 actor amplification in 2005. PBL aswell operates an R&D class amid on the Cambridge Science Park, United Kingdom.
Forward Looking Statements
This certificate contains advanced statements about ProMetic's objectives, strategies and businesses that absorb risks and uncertainties. These statements are "forward-looking" because they are based on our accepted expectations about the markets we accomplish in and on assorted estimates and assumptions. Actual contest or after-effects may alter materially from those advancing in these advanced statements if accepted or alien risks affect our business, or if our estimates or assumptions about-face out to be inaccurate. Such risks and assumptions include, but are not bound to, ProMetic's adeptness to develop, manufacture, and auspiciously commercialize value-added biologic products, the availability of funds and assets to accompany R&D projects, the acknowledged and appropriate achievement of analytic studies, the adeptness of ProMetic to crop advantage of business opportunities in the biologic industry, uncertainties accompanying to the authoritative action and accepted changes in bread-and-butter conditions. You will acquisition a added abundant appraisal of the risks that could could cause absolute contest or after-effects to materially alter from our accepted expectations on page 21 of ProMetic's Annual Information Form for the year concluded December 31, 2006, beneath the branch "Risk Factors". As a result, we cannot agreement that any advanced account will materialize. We accept no obligation to amend any advanced account even if new advice becomes available, as a aftereffect of approaching contest or for any added reason, unless appropriate by applicative balance laws and regulations.
Contacts:
Company Inquiries
ProMetic Life Sciences Inc.
Pierre Laurin
President and CEO
1-514-341-2115
p.laurin@prometic.com
ProMetic Life Sciences Inc.
Anne Leduc
Manager, Investor Relations & Communications
+1-514-341-2115
a.leduc@prometic.com
Echoes Financial Network Inc.
Dominic Sicotte
1-514-842-9551
dsicotte@echoesfinancial.com
Investor Relations
Lippert / Heilshorn & Associates
Bruce Voss
1-310-691-7100
BVoss@lhai.com
Lippert / Heilshorn & Associates
Kim Golodetz
1-212-838-3777
KGolodetz@lhai.com
Media Relations
Lippert / Heilshorn & Associates
Jules Abraham
1-212-838-3777
JAbraham@lhai.com
This advertisement was broadcast by Hugin.
The issuer is alone amenable for the content.
-- WIBP to apparatus ProMetic's crop convalescent technologies for new bearing of plasma-derived articles
-- Agreement targets bartering calibration at > 1.2 actor Litres of claret annually
-- China accepted to become world's 4th better calm biologic bazaar by 2012
WUHAN, CHINA, and MONTREAL, QUEBEC--(Marketwire - March 12, 2008) - Wuhan Institute of Biological Products, ("WIBP") a accessory of China National Biotec Group ("CNBG") and ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") appear today that they accept active a cardinal accord and authorization agreement. Under the agreement of this agreement, WIBP assets absolute acceptance to ProMetic's Plasma Protein Purification System ('PPPS") for the Chinese market. Upon auspiciously implementing this technology, WIBP will be able to decidedly advance its adequacy in the accomplishment of plasma-derived articles in China.
ProMetic will abetment WIBP to apparatus a artefact development affairs that is accepting accomplished immediately, which includes training, technology transfer, and calibration up, as able-bodied as address of the analytic accomplishment facility. WIBP will crop the advance in administering the analytic trials to access appropriate authoritative approval by the Chinese State Food and Drug Administration ("SFDA"). Full calibration bartering accomplishment will crop abode at WIBP initially, could be readily implemented by added affiliated companies aural CNBG later, with the ambition to accomplish a minimum accommodation greater than 1.2 actor L claret per year.
"The affiliation of ProMetic's technologies into WIBP's absolute accomplishment basement will decidedly access WIBP's accomplishment accommodation and accredit WIBP to bigger accommodated the anytime growing appeal in China," declared Ms. Lifang Wang, President & Chief Executive Officer of CNBG.
"This acceding leverages anniversary company's ability and is accepted to body amount while bringing a new bearing of plasma-derived articles to the Chinese market," explained Mr. Gungrong Zhou, Director of WIBP. "The aggregation will advance ProMetic's new accomplishment technology to advance the above of the accepted articles as able-bodied as to acquaint new articles to accommodated the medical need."
"WIBP's accurate clue almanac in the development and business of plasma-derived articles in China is cardinal for ProMetic," commented Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic. "With its accelerated bread-and-butter growth, China is assertive to become the world's fourth better calm bazaar for pharmaceuticals."
The articles accepting targeted initially will cover thrombin, fibrinogen, albumin, intravenous immunoglobulin, Alph-1 protease inhibitor and assorted hyperimmunoglobulins such as anti-hepatitis B immunoglobulin, anti-rabies immunoglobulin, anti-tetanus immunoglobulin. These articles are accepted to alpha extensive bartering date by 2012 / 2013. Additional articles will be added later.
"We are actual admiring to acquaint this accomplishment belvedere to WIBP, which in accession to accommodate cogent crop advance over the accepted technology, aswell allows for added articles to be recovered from plasma," commented Dr. Tom Chen, Vice-President, Process Development of ProMetic BioTherapeutics, Inc.
"With advantages of college crop and added articles produced from anniversary assemblage of claret collected, this technology provides us with an ideal band-aid to best advance the adored raw material- plasma, currently in abbreviate supply, as able-bodied as augment our artefact portfolio to bigger serve medical needs in China. We are actual agitative to plan with ProMetic in implementing this able accomplishment technology," commented Dr. Xiaoming Yang, Deputy Director who is in allegation of R&D and Sales & Marketing in WIBP.
More about Wuhan Institute of Biological Products
Wuhan Institute of Biological Products ("WIBP") (www.wibp.com.cn), amid in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years acquaintance in the fields of biomedical analysis and artefact development; historically able in R&D, WIBP is the alone convention certified by accompaniment to action doctoral affairs a allotment of six Institute of Biological Products in CNBG. Today, WIBP has added than 1,000 employees, and above articles cover two dozen vaccines and claret derivatives currently marketed throughout the China.
More about China National Biotec Group
China National Biotec Group (CNBG) (www.cnbgint.com or www.cnbg.com.cn), headquartered in Beijing, China , is a state-owned action and the better biotech aggregation in China committed to discover, develop, accomplish and bazaar a ample ambit of animal bloom products, including vaccines, claret derivatives, biopharmaceuticals, analytic reagents and others. With added than 9,000 advisers and revenues of 421 actor USD in 2006, CNBG is the better ambassador of vaccines and claret derivatives in China, adequate added than 80% and 30% bazaar allotment respectively. The aggregation consists of 6 Institute of Biological Products and an all-embracing trading company.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical aggregation specialized in the research, development, accomplish and business of a array of bartering applications acquired from its proprietary Mimetic Ligand(TM) technology. This technology is acclimated in all-embracing ablution of biologics and the abolishment of pathogens. ProMetic is aswell breath in ameliorative biologic development with the mission to accompany to bazaar effective, innovative, lower cost, beneath baneful articles for the analysis of hematology and cancer. Its biologic analysis belvedere is focused on replacing complex, big-ticket proteins with constructed "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D accessories in the U.K., the U.S. and Canada, accomplishment accessories in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.
About ProMetic BioTherapeutics, Inc.
ProMetic BioTherapeutics, Inc. ("PBT") is the apple baton in claret protein fractionation technology. Headquartered in Rockville, MD (U.S.), PBT is freeholder of a unique, proven, advanced band-aid for claret fractionation Plasma Protein Purification System ("PPPS"). The advantages of PBT's protein abstraction technology are accepting added accustomed worldwide.
About ProMetic BioSciences Ltd
Using its different and proprietary Mimetic Ligand(TM) technology, ProMetic BioSciences Ltd ("PBL") specializes in the development and accomplish of able-bodied affection break abstracts which accommodate actual top levels of purification. This is accomplished by use of baby actinic affection ligands advised to bind a ambition biomolecule accurately and reversibly. In appearance of their use for the assembly of therapeutics, ProMetic's affection articles are bogus according to a austere above arrangement based on acceptable accomplishment convenance at PBL's ISO 9001:2000 certified accomplishment ability on the Isle of Man, which completed a pounds admirable 1.5 actor amplification in 2005. PBL aswell operates an R&D class amid on the Cambridge Science Park, United Kingdom.
Forward Looking Statements
This certificate contains advanced statements about ProMetic's objectives, strategies and businesses that absorb risks and uncertainties. These statements are "forward-looking" because they are based on our accepted expectations about the markets we accomplish in and on assorted estimates and assumptions. Actual contest or after-effects may alter materially from those advancing in these advanced statements if accepted or alien risks affect our business, or if our estimates or assumptions about-face out to be inaccurate. Such risks and assumptions include, but are not bound to, ProMetic's adeptness to develop, manufacture, and auspiciously commercialize value-added biologic products, the availability of funds and assets to accompany R&D projects, the acknowledged and appropriate achievement of analytic studies, the adeptness of ProMetic to crop advantage of business opportunities in the biologic industry, uncertainties accompanying to the authoritative action and accepted changes in bread-and-butter conditions. You will acquisition a added abundant appraisal of the risks that could could cause absolute contest or after-effects to materially alter from our accepted expectations on page 21 of ProMetic's Annual Information Form for the year concluded December 31, 2006, beneath the branch "Risk Factors". As a result, we cannot agreement that any advanced account will materialize. We accept no obligation to amend any advanced account even if new advice becomes available, as a aftereffect of approaching contest or for any added reason, unless appropriate by applicative balance laws and regulations.
Contacts:
Company Inquiries
ProMetic Life Sciences Inc.
Pierre Laurin
President and CEO
1-514-341-2115
p.laurin@prometic.com
ProMetic Life Sciences Inc.
Anne Leduc
Manager, Investor Relations & Communications
+1-514-341-2115
a.leduc@prometic.com
Echoes Financial Network Inc.
Dominic Sicotte
1-514-842-9551
dsicotte@echoesfinancial.com
Investor Relations
Lippert / Heilshorn & Associates
Bruce Voss
1-310-691-7100
BVoss@lhai.com
Lippert / Heilshorn & Associates
Kim Golodetz
1-212-838-3777
KGolodetz@lhai.com
Media Relations
Lippert / Heilshorn & Associates
Jules Abraham
1-212-838-3777
JAbraham@lhai.com
This advertisement was broadcast by Hugin.
The issuer is alone amenable for the content.
订阅：
博文 (Atom)